Abstract
Recently, various mutations within the Abl sequence have been described that negatively affect imatinib binding to Bcr/Abl resulting in cellular resistance of chronic myeloid leukemia (CML) cells. So far, little is known as to whether these mutations are preexisting or develop under imatinib therapy as current mutation analyses are limited by a low sensitivity of approximately 1:2 (50%) to 1:5 (20%). By combining peptide nucleic acid (PNA)-based DNA clamping with a fluorescence hybridization probe assay, we developed a new and highly sensitive technique for the detection of known mutations within the Bcr/Abl kinase domain. With this approach we investigated 19 cases of CML refractory to imatinib treatment before and during therapy. By clamping of wild-type Abl through PNA we could effectively enhance the detection sensitivity for the Bcr/Abl mutations Thr315Ile, Glu255Lys, and Tyr253His such that 1 mutant cDNA molecule could be detected in 500 negatives (0.2%). We observed in one case that a Gly255Lys mutation was detectable before treatment. By DNA analysis of buccal swaps, a genetic polymorphism could be excluded. In two cases clonal evolution of known mutations developed gradually under treatment. In another case an initially detectable Tyr253His mutation disappeared after therapy onset but was again observed after 6 weeks of imatinib treatment. Preexisting and evolving Bcr/Abl mutations associated with an unfavorable prognosis could be safely detected by the presented technique. This may facilitate risk stratification in CML and may serve as a model for individualized molecular monitoring and therapeutic strategies in other malignant diseases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the abl tyrosine kinase on the growth of bcr-abl positive cells. Nature Med 2:561–566
le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F, Gambacorti-Passerini C (1999) In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 91:163–168
le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R, Gambacorti-Passerini C (2000) Induction of resistance to the abelson inhibitor imatinib in human leukemic cells through gene amplification. Blood 95:1758–1766
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by bcr-abl gene mutation or amplification. Science 293:876–880
Barthe C, Cony-Makhoul P, Melo JV, Mahon JR (2001) Roots of clinical resistance to STI-571 cancer therapy. Science 293:2163a
Hochhaus A, Kreil S, Corbin A, La Rosee P, Lahaye T, Berger U, Cross NC, Linkesch W, Druker BJ, Hehlmann R (2001) Roots of clinical resistance to STI-571 cancer therapy. Science 293:2163a
von Bubnoff N, Schneller F, Peschel C, Duyster J (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359:487–491
Shah NP, Nicoll JM, Gorre ME, Paquette RL, Ford J, Sawyers CL (2001) Resistance to Gleevec: sequence analysis reveals a spectrum of BCR/ABL kinase domain mutations in both acquired- and de novo- resistant cases of chronic myelogenous leukemia (CML) in myeloid blast crisis. Blood 98:770a
Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP (2002) High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99:3472–3475
Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D, Ottmann OG, Koeffler HP (2002) Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99:1860–1862
Kreil S, Müller MC, Lahaye T, La Rosée P, Corbin AS, Schoch C, Cross NCP, Berger U, Rieder H, Druker BJ, Gschaidmeier H, Hehlmann R, Hochhaus A (2001) Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy. Blood 98:435a
Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117–125
Gambacorti-Passerini C, Mologni L, Bertazzoli C, le Coutre P, Marchesi E, Grignani F, Nielsen PE (1996) In vitro transcription and translation inhibition by anti-promyelocytic leukemia (PML)/retinoic acid receptor alpha and anti-PML peptide nucleic acid. Blood 1411–1417
Ørum H, Nielsen PE, Egholm M, Berg RH, Burchardt O, Stanley C (1993) Single base pair mutation analysis by PNA directed PCR-clamping. Nucleic Acids Res 21:5332–5336
Landt O, Lass U, Wallen M, Hänfler J (2002) One-step real-time detection of minimal amounts of single-base mutated alleles and their quantification using PNA-mediated PCR-clamping and hybridization probes. Nucleic Acids Res, in press
Kreuzer KA, Lass U, Bohn A, Landt O, Siegert W, Huhn D, Schmidt CA (1999) LightCycler technology for the quantitation of bcr/abl fusion transcripts. Cancer Res 59:3171–3174
Kreuzer KA, Lass U, Landt O, Nitsche A, Ellerbrok H, Pauli G, Laser J, Huhn D, Schmidt CA (1999) Highly sensitive and specific fluorescence RT-PCR assay for the pseudogene free detection of beta-actin transcripts as quantitative reference. Clin Chem 45:297–300
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037
Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99:1928–1937
Kreuzer KA, Lass U, Nagel S, Ellerbrok H, Pauli G, Pawlaczyk-Peter B, Siegert W, Huhn D, Schmidt CA (2000) Applicability of an absolute quantitative procedure to monitor intra-individual bcr/abl transcript kinetics in clinical samples of chronic myelogenous leukemia patients. Int J Cancer 86:741–746
Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lay JL, Philippe N, Facon T, Fenaux P, Preudhomme C (2002) Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100:1014–1018
le Coutre P, Kreuzer KA, Na IK, Lupberger J, Holdhoff M, Appelt C, Schwarz M, Müller C, Gambacorti-Passerini C, Platzbecker U, Bonnet R, Ehninger G, Schmidt CA (2002) Determination of α-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood Cells Mol Dis 28:75–85
Acknowledgements
This work was supported by the Deutsche José Carreras Leukämie Stiftung e.V., grant no. DJCLS R-01/12 f.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/s00277-003-0690-5.
Rights and permissions
About this article
Cite this article
Kreuzer, KA., le Coutre, P., Landt, O. et al. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann Hematol 82, 284–289 (2003). https://doi.org/10.1007/s00277-003-0644-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-003-0644-y